Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GD2IL18CART |
| Synonyms | |
| Therapy Description |
GD2IL18CART comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets GD2 and an inducible IL-18 that depends on target engagement, which potentially increases cytokine production and lysis of GD2-expressing cells, leading to tumor growth inhibition (PMID: 38593230). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GD2IL18CART | GD2 Immune Cell Therapy 7 | GD2IL18CART comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets GD2 and an inducible IL-18 that depends on target engagement, which potentially increases cytokine production and lysis of GD2-expressing cells, leading to tumor growth inhibition (PMID: 38593230). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|